Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival. While allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for myelofibrosis, the only approved and reimbursed pharmacotherapy for non-HSCT candidates in Belgium is ruxolitinib. These updated recommendations are based on a consensus reached during two meetings and provide guidance for ruxolitinib administration in myelofibrosis patients considering the particularities of Belgian reimbursement criteria. In Belgium, ruxolitinib is indicat... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Schlagwörter: | Biomarkers / Clinical Decision-Making / Combined Modality Therapy / Disease Management / Disease Susceptibility / Drug-Related Side Effects and Adverse Reactions / Hematopoietic Stem Cell Transplantation / Humans / Janus Kinase Inhibitors / Molecular Targeted Therapy / Nitriles / Platelet Count / Primary Myelofibrosis / Prognosis / Pyrazoles / Pyrimidines / Treatment Outcome / Belgium / Ruxolitinib / anemia / myelofibrosis / reimbursement / splenomegaly / symptom burden / transplantation |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26588353 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/263876 |